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Background: Human Papillomavirus (HPV) infection is particularly burdensome for women infected with human
immunodeficiency virus (HIV), which increases their risk of developing cervical lesions and cancer (CC). We
conducted a molecular study of the distribution of cervical HPV genotypes and the risk factors for this infection in
HIV-infected Brazilian women.
Findings: Cervical and endocervical samples for Papanicolaou screening and HPV detection were collected from 178
HIV-infected women using highly active antiretroviral therapy (HAART) of Maringá city/Brazil. Risk factors were assessed
using a standardized questionnaire, and the data regarding to HIV infection from medical records. HPV was detected
by polymerase chain reaction (PCR), and genotyping using PCR-restriction fragment length polymorphism analysis. HIV
infection was well controlled, but women with a current CD4+ T lymphocyte count between 200–350 cells/mm3
(37.6%) had a two-fold greater risk of HPV infection than those with > 350 cells/mm3 (26.4%). HPV was associated with
parity ≥3, hormonal contraceptive use and current smoker. HPV infection occurred with high frequency (46.6%) but a
low frequency of cervical abnormalities was detected (7.30%), mainly low-grade squamous intraephitelial cervical
lesions (LSIL) (84.6%). A high frequency of multiple HPV infections was detected (23.0%), and the most frequent HPV
genotype was HPV-72 (6.7%), followed by −16, -31 and -51 (6.14% each).
Conclusions: We showed that HAART use does not protect HIV-infected women from HPV, but appear to exert some
protection against cervical lesions development. This study provides other important information about risk factors and
cervical HPV in HIV-infected women, which can contribute to planning protocols.
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It is estimated that in 2020, cervical cancer (CC) will be
diagnosed in over 665,035 women worldwide, and 357,852
will die as a result [1]. The frequency of CC is much
higher in underdeveloped or developing countries than it
is in developed countries [2]. In Brazil, CC is the third
most common cancer among women, with 17.540 new
cases diagnosed in 2012 [3].
The association between persistent high-risk (HR) Human
Papillomavirus (HPV) and CC has been well established [4].
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distribution, and reproduction in any mediumimmunodeficiency virus (HIV)-infected women, as they
are more vulnerable to infection and are less likely to
clear the virus, which increases their risk of developing
cervical lesions and cancer. Moreover, in HIV-infected
women, CC responds poorly to the recommended ther-
apies, is more aggressive, and in cases of recurrence,
has a worse prognosis [5]. In Brazil, approximately
180,000 HIV-positive individuals are undergoing highly
active antiretroviral therapy (HAART) administered by
the Public Health System [6]. While this therapy has
been associated with a substantial reduction in AIDS-
related mortality, its role in preventing HPV infection
and progression to CC is still poorly studied and con-
troversial [6,7].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Figure 1 Electrophoretic analysis of HPV genotyping by PCR-
restriction fragment length polymorphism analysis (PCR-RFLP)
using HpyCH4V in 8% polyacrylamide gel stained with
ethidium bromide. Sample A1, genotype −31 (HR) in single HPV
infection (216, 108, 94 base pairs-pb); A2, genotype −56 (HR) in single
HPV infection (244, 121 pb); A3, genotypes −13 (LR), -16 and −58 (HR)
in multiple HPV infection (244, 216, 191, 103, 99, 91 e 89 pb); A4,
genotype −51 (HR) in single HPV infection (171, 147, 137 pb); A5,
genotypes −16 (HR) and −61 (LR) on double HPV infection (216,
191, 171, 147, 137). M, molecular weight marker (25 base pairs).
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women are more commonly infected with non-16 and
−18 HR-HPV genotypes, such as 52 and 58 [8,9]. Given
that current vaccines target HPV -16/-18, these findings
may have important implications for future HPV vac-
cines that target other types of HPV that are associated
with disease risk in HIV-infected women [10].
Considering that epidemiological data from different
populations are required for public policies addressing
CC prevention in HIV-infected women and that few
studies from Brazil and Latin America have collected
these data, we conducted a molecular study of the distri-
bution of cervical HPV genotypes and the risk factors as-
sociated with this infection in HIV-infected Brazilian
women.
In total, 178 HIV-infected women using HAART, aged
18 to 66 years, who attended the Specialized Assistance
Service (SAE) for sexually transmitted diseases (STD)/
AIDS of Maringá city/Southern Brazil, from April 1 to
October 30, 2011, were included. The inclusion criterion
required that the women had been diagnosed twice with
HIV/AIDS using different methods and using HAART.
The exclusion criteria were previous hysterectomy, current
or recent pregnancy, age younger than 18 years, and no
history of sexual activity.
Of the 424 HIV-infected women enrolled in the SAE,
100 were excluded, and a total of 324 were eligible for
the study. The sample size was calculated with an HPV
prevalence of 50%, confidence interval of 95%, error esti-
mate of 5%. With an increase of 10% for possible partici-
pant losses, the total sample size was fixed at 178
randomly selected women.
The women were interviewed using a standardized
questionnaire to obtain socio-economic and demographic
information, obstetric and gynecologic history and data on
their sexual behavior. Data regarding HIV infection were
obtained from SAE medical records. A single nursing con-
tacted all of the women, administered the questionnaire
and collected the cervical samples. This project was ap-
proved by the Committee for Ethics in Research Involving
Humans at the State University of Maringá (UEM)/
Paraná, Brazil (nº 085/2011).
Ecto/endocervical samples were collected with an Ayre’s
spatula and cytobrush for cervical cytology (Papanicolaou
screening) and polymerase chain reaction (PCR); the sam-
ples were suspended in 1 ml of 0.9% NaCl solution and
stored at -20°C. The cytological smears were sent to the
Clinical Cytology Laboratory of UEM and were graded ac-
cording to the Bethesda System [11]. Genomic DNA was
extracted using an AxyPrep™ Body Fluid Viral DNA/RNA
Miniprep kit (Axygen, CA, USA). PCR amplification of
HPV was carried out using the following primers: MY09
(5’CGTCCMAARGGAWACTGATC-3’)/MY11(5’-GCMCA
GGGWCATAAYAATGG-3’). Genotyping by PCR-restrictionfragment length polymorphism analysis using HpyCH4V
[12] was performed. Co-amplification of the human β-
globin gene was performed, as an internal control, using
the following primers under the same conditions as those
used for HPV-PCR: GH20 (5’-GAAGAGCCAAGGACA
GGTAC-3’)/PC04 (5’-CAACTTCATCCACGTTCACC-3′)
(Figure 1).
Statistical analysis was performed using Open Source
Epidemiologic Statistics for Public Health/OpenEpi, Ver-
sion 2.3.1. All variables were expressed as absolute and
relative frequencies. For univariate analysis, categorical
variables were compared with HPV infection by χ2-
square and Fisher’s exact test. Some variables of interest
with p < 0.20 were selected for logistic regression ana-
lysis. A crude odds ratio (OR) and 95% confidence inter-
val (CI) were calculated. A p-value < 0.05 was considered
significant.
Most HIV-infected women showed excellent control of
the HIV infection, based on HAART proper use (79.2%),
high current CD4+ T lymphocyte count (37.6% with 200–
350 cells/mm3 and 26.4% with > 350 cells/mm3) and low
current viral load (58.4% < minimum limit and 38.8% be-
tween the minimum limit and 100 copies/ml).
Univariate analysis revealed an association between
HPV infection and parity ≥ 3 (p = 0.01), not undergoing
Table 1 Univariate analysis of epidemiologic and HIV
infection data in 178 women and association with HPV
Variables n (%) HPV
(%)
OR (95% CI)a p valueb
Age ranges (years)
18-30 28 (15.7) 60.7 1.93 (0.94-1.99) 0.13
31-40 60 (33.7) 43.3 0.96 (0.47-1.95) 0.89
> 40 90 (50.6) 44.4 1.0
Education (years)
< 8 85 (47.8) 45.9 1.69 (0.93-3.06) 0.84
≥ 8 93 (52.2) 47.3 1.0
Marital status
Married 93 (52.2) 45.2 1.0
Unmarried 31 (17.4) 48.4 1.14 (0.46-2.77) 0.75
Widowed 54 (30.3) 48.1 1.13 (0.55-2.33) 0.72
Skin color
White 114 (64.0) 42.1 1.0
Not white 64 (36.0) 54.7 1.66 (0.86-3.22) 0.10
Menarche (years)
< 13 95 (53.4) 43.2 0.74 (0.39-1.40) 0.32
≥ 13 83 (46.6) 50.6 1.0
Age of sexual debut
(years)
< 18 112 (62.9) 45.5 0.89 (0.46-1.71) 0.70
≥ 18 66 (37.1) 48.5 1.0
Sexual partners
(number)
1 16 (9.0) 56.2 1.0
2-7 74 (41.6) 44.6 0.63 (0.18-2.10) 0.39
> 7 88 (49.4) 46.6 0.68 (0.20-2.22) 0.47
Parity (number)
0 20 (11.2) 70.0 1.0
1-2 67 (37.7) 49.2 0.42 (0.12-1.35) 0.10




Yes 143 (80.3) 42.7 1.0
No 35 (19.7) 62.9 2.27 (1.01-5.23) 0.03
Hormonal
contraceptive use
Yes 135 (75.9) 43.7 0.61 (0.29-1.30) 0.16
No 43 (24.1) 55.8 1.0
Gynecologic infections
Yes 127 (71.3) 48.0 1.22 (0.60-2.47) 0.55
No 51 (28.7) 43.1 1.0
Table 1 Univariate analysis of epidemiologic and HIV




0 55 (30.9) 40.0 1.0
1-2 93 (52.2) 48.4 1.41 (0.68-2.92) 0.32
≥ 3 30 (16.9) 53.3 1.71 (0.64-4.64) 0.23
Cigarette smoking
Yes 35 (19.7) 65.7 2.76 (1.15-6.67) 0.01
No 100 (56.2) 41.0 1.0
Ex-smoker 43 (24.1) 44.2 0.41 (0.15-1.14) 0.05
Period of HIV
infection (years)
< 5 76 (42.7) 56.6 1.72 (0.79-3.75) 0.13
5-10 51 (28.6) 35.5 0.72 (0.30-1.72) 0.41
> 10 51 (28.6) 43.1 1.0
HAART correct use
Yes 141 (79.2) 46.8 1.04 (0.47-2.28) 0.92




< 200 15 (8.4) 66.7 2.76 (0.81-9.92) 0.06
200-350 67 (37.6) 56.3 1.78 (0.76-4.16) 0.14
> 350 47 (26.4) 42.0 1.0
CD4+ T lymphocyte
range (cells/mm3)
< 200 64 (35.9) 51.5 1.21 (0.53-2.76) 0.62
200-350 67 (37.6) 41.8 0.82 (0.36-1.85) 0.59
> 350 47 (26.4) 46.8 1.0
Recent viral load
(copies/ml)
< L min 104 (58.4) 43.3 1.0
1-100.000 69 (38.8) 49.3 1.27 (0.66-2.46) 0.43
> 100.000 5 (2.8) 80.0 5.24 (0.52-27.6) 0.17
Viral load range
(copies/ml)
1-100.000 50 (28.1) 50.0 1.0
> 100.000 128 (71.9) 45.3 0.83 (0.41-1.68) 0.57
aOdds ratio (OR) 95% confidence interval (CI).
bA p-value < 0.05 was considered significant.
Highly active antiretroviral therapy (HAART).
Papanicolaou secreening (Pap screening).
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ing (p = 0.01), previous smoking (p = 0.05) and current
CD4+ T lymphocyte count < 200 cells/mm3 (p = 0.06)
(Table 1).
After logistic regression, HPV infection was associated
with parity ≥ 3 (p < 0.01; OR = 0.17, 0.05-0.55), hormonal
Table 2 Multivariate analysis of epidemiologic and HIV
infection data in 178 women and association with HPV
Variables Adjusted OR 95% CIa p valueb
Skin color 1.46 0.71-3.02 0.30
Parity number = 0 1.45 0.14-1.45 0.18
Parity number ≥ 3 0.17 0.05-0.55 < 0.01
History of Pap smear in
the past three years
2.08 0.86-5.00 0.10
Hormonal contraceptives use 0.40 0.17-0.92 0.03
Smoker 3.04 1.24-7.46 0.01
Ex-smoker 1.42 0.62-3.24 0.40






CD4+ T lymphocyte < 200
(cells/mm3)
3.04 0.86-10.6 0.08
CD4+ T lymphocyte < 200–350
(cells/mm3)
1.66 1.05-2.62 0.02
aOdds ratio (OR) 95% confidence interval (CI).
bA p-value < 0.05 was considered significant.
Papanicolaou secreening (Pap screening).
Cells per cubic millimeter (cells/mm3).
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0.92), current smoking (p = 0.01; OR = 95% CI = 3.04,
0.24-7.46), and current CD4+ T lymphocyte count < 200
cells/mm3 (p = 0.08; OR = 3.04, 95% CI = 0.86-10.6 ) and
between 200–350 cells/mm3 (p = 0.02; OR = 1.66, 95%
CI = 1.05-2.62 ) (Table 2).
A total of 7.3% (n = 13) of the women showed cervical
abnormalities, of which 84.6% (n = 11) were low-grade
squamous intraepithelial cervical lesions (LSIL) and 7.7%
(n = 1) for both atypical squamous cervical cells (ASC)






n % n % n
NILM (n = 165) 14 8.5 23 13.4 #37
ASC-US (n = 1) - - - - -
ASC-H - - - - -
(n = 1)
LSIL (n = 11) 2 18.2 3 27.3 5
Total (n = 178) ##16 9.0 ##26 14.6 42
Pap (Papanicolaou) screening with normal cervical cells (NILM).
Atypical squamous cervical cells of undetermined significance (ASC-US).
Atypical squamous cervical cells could not be excluded a high-grade squamous intr
Low-grade squamous intraepithelial cervical lesions (LSIL).
*Multiple HPV infections without high- risk HPV (HR-HPV) involvement (i.e. low-risk-
**Multiple HPV infections with HR-HPV involvement (i.e. HR and/or undetermined-ri
#HPV infection was more prevalent in women with normal cytology (NILM) (p = 0.02
##LR- and HR-HPV were detected with similar prevalence in single or multiple HPV i
###In multiple HPV infections, HR-HPV was more prevalent than LR in women with Nnot be excluded a high-grade squamous intraepithelial
cervical lesion (ASC-H) (Table 3).
The frequency of HPV was 46.6% (n = 83), and in 23.0%
of participants (n = 41) multiple HPV genotypes were de-
tected. Low-risk (LR)-HPV was detected in 14.6% (n = 26),
and HR-HPV was detected in 32.0% (n = 57) of the
women (p < 0.01). LR and HR-HPV showed similar fre-
quencies in single and multiple infections (p = 0.0727 and
0.0949, respectively). However, in multiple HPV infec-
tions, HR-HPV was more frequent than LR-HPV in both
women with normal cervical cells (NILM) (n = 26, 15.8%
and n = 7, 4.2%, respectively) and those with LSIL (n = 31,
17.4% and n = 10, 5.6%, respectively) (p = 0.01). HPV in-
fection occurred most commonly in women with NILM
(n = 72, 40.4%) (p = 0.022) (Table 3).
A total of 37 different HPV genotypes were detected
in the 178 women studied. The most frequent HR-HPV
genotypes were HPV 16, 31 and 51 (6.18% each); HPV
66 and 58 (3.4% each); HPV 59 and 82 (2.8% each); and
HPV 56 and 69 (2.3% each). The most commonly de-
tected LR-HPV genotypes were HPV 72 (6.74%); HPV
61 (3.9%); and HPV 11, 70, 74 and 83 (2.3% each)
(Table 4).
In the present study, we found that although HIV infec-
tion was well controlled, women with a current CD4+ T
lymphocyte count between 200–350 cells/mm3 (37.6%)
had a two-fold greater risk of HPV infection than those
with > 350 cells/mm3 (26.4%). However, our results also
showed that although the frequency of HPV was high
(46.6%), a low frequency of cervical abnormalities was de-
tected (7.30%), mainly LSIL (84.6%). Recently, it was re-
ported that HPV frequency was much lower (6.7%) in
HIV-uninfected women in the city in which this study was
conducted [13]. Therefore, HAART use or/and the com-
prehensive care delivered to these patients through theh HIV
Multiple HPV infections
*LR-HPV **HR-HPV Total
% n % n % n %
88.1 7 4.2 ###26 15.8 #33 20.0
- - - 1 100 1 100
- 1 100 - - 1 100
11.9 2 18.2 ###4 36.4 6 54.6
100.0 ##10 5.6 ##31 17.4 41 23.0
aepithelial cervical lesion (ASC-H).
LR and/or undetermined-risk HPV).
sk and/or LR-HPV).
2).
nfections (p = 0.0727 and 0.0949, respectively).
ILM and LSIL (p = 0.01).
Table 4 Distribution of 37 HPV genotypes detected in
178 women with HIV
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http://www.infectagentscancer.com/content/9/1/6SAE appears to exert some protection against cervical le-
sions development in this population.
HPV infection was positively associated with parity
number ≥ 3, hormonal contraceptive use and smoker. A
relationship between these risk factors and CC has been
reported in HIV-uninfected women [14,15]. Our results
suggest that they are also associated with HPV infection
in HIV-infected women. These data are important for
public policies targeting HIV-infected women to prevent
HPV infection and CC.
Multiple HPV infections were frequently detected, oc-
curring in half of the HPV positive women; similar findings
have already been widely reported [5,10,14]. Interestingly,
the most common HPV genotype was −72 (LR, 8.6%),
followed by HPV −16, -31 and −51 (7.9% each). These data
differ from those described by others in that HR-HPV was
detected more frequently. Nonetheless, they are in part
agreement with studies showing that these women are
commonly infected with the non-18/-16 HR-HPV geno-
types [8,9].
In conclusion, we acknowledge that we did not include
HIV-uninfected women for comparison. However, we have
provided very important information about the risk factors
associated with HPV frequency and genotypes in HIV-
infected women, and this information can contribute to
planning protocols for CC prevention in these patients. It
should be noted that the STD/AIDS program of the Brazil-
ian Ministry of Health distributes HAART free of charge
and ensures its use. This program also provides compre-
hensive care to HIV-positive patients, which certainly con-
tributed to the low frequency of cervical lesions (most were
LSIL) we observed. This study can serve as a model for the
populations of other Latin American countries.
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